CPX1 Antibody

What is CPXM1/CPX1 and what are its key biological functions?

Carboxypeptidase X1 (CPXM1), also known as CPX1, belongs to the carboxypeptidase family of proteins. This protein contains a discoidin domain and a carboxypeptidase domain, though interestingly, it appears to lack the residues necessary for carboxypeptidase enzymatic activity . While most carboxypeptidases are metalloproteases that cleave amino acids from the C-terminus of proteins and peptides, several members of the carboxypeptidase X family, including CPXM1, have lost their catalytic activity while retaining other functional properties .

CPXM1 has been genetically associated with several conditions, including Mirror Movements 1 (a neurological disorder where intentional movements on one side of the body are mirrored by involuntary movements on the opposite side) and Nephrotic Syndrome Type 1 (a kidney disorder) . These disease associations suggest potential roles in neurological development and kidney function, though the precise molecular mechanisms remain to be fully elucidated.

What are the key technical specifications for commercially available CPX1/CPXM1 antibodies?

Based on available product information, researchers have access to several well-characterized antibodies against CPXM1 with the following specifications:

Both antibodies require specific storage conditions for optimal stability and performance:

• Long-term storage (12 months): -20 to -70°C as supplied

• Short-term storage (1 month): 2 to 8°C under sterile conditions after reconstitution

• Medium-term storage (6 months): -20 to -70°C under sterile conditions after reconstitution

Important technical notes include using manual defrost freezers and avoiding repeated freeze-thaw cycles as these can compromise antibody integrity and experimental reproducibility . For applications beyond Western blotting, researchers should determine optimal dilutions empirically for their specific experimental systems.

How should researchers validate the specificity of CPX1/CPXM1 antibodies?

Validating antibody specificity is a critical step in ensuring experimental reliability. For CPX1/CPXM1 antibodies, a multi-faceted validation approach is recommended:

Control Samples Analysis

• Positive controls: Use recombinant CPXM1 proteins or lysates from cells/tissues known to express CPXM1

• Negative controls: Include samples from CPXM1 knockout/knockdown systems, non-expressing tissues, or isotype-matched antibody controls

• Expected results: For Western blots, anticipate a single band at the predicted molecular weight of CPXM1 (~80-90 kDa)

Cross-reactivity Assessment

• Test against related proteins, particularly CPXM2, which is an important paralog of CPXM1

• Be aware that the Human CPXM1 Biotinylated Antibody shows approximately 30% cross-reactivity with recombinant mouse CPXM1 in Western blots

• Consider cross-species reactivity when designing experiments with murine models

Molecular Validation Methods

• Immunodepletion: Pre-incubate the antibody with recombinant CPXM1 before application; this should eliminate specific binding

• Genetic validation: Compare staining patterns between wild-type and CPXM1-deficient samples

• Multiple antibody approach: Use several antibodies targeting different epitopes of CPXM1 to confirm consistent results

Thorough documentation of validation experiments is essential for publication and ensuring reproducibility. Include detailed descriptions of validation methods and results in your experimental protocols and manuscripts.

What are the optimal protocols for using CPX1/CPXM1 antibodies in Western blot applications?

Based on technical product information and general best practices, here is a methodological approach for Western blot applications using CPX1/CPXM1 antibodies:

Sample Preparation

• Extract proteins using RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0)

• Include protease inhibitor cocktail to prevent degradation

• Determine protein concentration using BCA or Bradford assay

• Prepare samples in Laemmli buffer with 5% β-mercaptoethanol

• Heat at 95°C for 5 minutes (verify this does not affect CPXM1 detection)

Gel Electrophoresis and Transfer

• Use 7-10% SDS-PAGE gels for optimal resolution of CPXM1 (~80-90 kDa)

• Load 20-50 μg of total protein per lane

• Include molecular weight markers and positive controls

• Transfer to PVDF membrane (recommended for larger proteins like CPXM1)

Antibody Incubation

• Block membrane with 5% non-fat dry milk or BSA in TBST

• For human samples: Apply Human CPXM1 Biotinylated Antibody at 0.1 μg/mL

• For mouse samples: Apply Mouse CPXM1 Antibody at optimized concentration

• Incubate overnight at 4°C with gentle agitation

• Wash thoroughly with TBST (3-5 washes, 5-10 minutes each)

Detection

• For biotinylated antibodies: Apply streptavidin-HRP conjugate

• For non-biotinylated antibodies: Use appropriate species-specific secondary antibody

• Develop using chemiluminescent substrate

• Expected result: Band at ~80-90 kDa for CPXM1

Quantification

• Use image analysis software for densitometry

• Normalize to appropriate loading controls (β-actin, GAPDH)

• Compare relative expression between samples

Remember that optimal dilutions should be determined by each laboratory for each application . Document all modifications to this basic protocol to ensure reproducibility across experiments.

What approaches can researchers use to troubleshoot non-specific binding with CPX1/CPXM1 antibodies?

Non-specific binding can complicate interpretation of results when using CPX1/CPXM1 antibodies. Here are methodological approaches to address this common issue:

Optimization of Blocking Conditions

• Test different blocking agents (BSA, casein, commercial blockers)

• Increase blocking time (from 1 hour to overnight)

• Add blocking agent to antibody dilution buffers (0.5-5%)

Washing Optimization

• Increase washing stringency with higher detergent concentrations

• Extend washing times (15-30 minutes per wash)

• Add low concentrations of SDS (0.01-0.05%) to wash buffers

Antibody Titration

• Create a dilution series to identify optimal concentration

• For Human CPXM1 Biotinylated Antibody, start at 0.1 μg/mL and adjust

• Sometimes lower antibody concentrations paradoxically improve signal-to-noise ratio

Sample-Specific Modifications

• For tissue samples: Consider additional clearing steps

• For cell lysates: Pre-clear with Protein A/G beads

• For recombinant proteins: Include carrier proteins

Cross-Reactivity Mitigation

• Pre-adsorb antibody with proteins from cross-reacting species

• Be aware of the 30% cross-reactivity between human CPXM1 antibody and mouse CPXM1

• Consider using more specific monoclonal antibodies if available

Technical Analysis of Problematic Results

• Multiple bands: May indicate protein degradation, isoforms, or cross-reactivity

• High background: Often related to insufficient blocking or washing

• No signal: Check protein transfer, antibody viability, and detection system

Document all troubleshooting steps systematically to identify the most effective protocol modifications for your specific experimental system.

How can CPX1/CPXM1 antibodies be utilized in protein-protein interaction studies?

Given that CPXM1 is believed to be involved in cell-cell interactions , protein-protein interaction studies are particularly relevant. Here are methodological approaches leveraging CPX1/CPXM1 antibodies for such research:

Co-Immunoprecipitation (Co-IP)

• Lyse cells in mild buffer (150 mM NaCl, 1% Triton X-100, 50 mM Tris, pH 7.4)

• Pre-clear lysate with Protein A/G beads

• Incubate with CPXM1 antibody overnight at 4°C

• Capture antibody-protein complexes with Protein A/G beads

• Elute and analyze by Western blot for potential interaction partners

Proximity Ligation Assay (PLA)

• Fix cells or tissues appropriately

• Apply primary antibodies against CPXM1 and potential interaction partner

• Add PLA probes with oligonucleotides

• Conduct ligation and amplification

• Analyze fluorescent signals indicating proximity (<40 nm)

High-Throughput Screening Approaches

• Consider adapting the PolyMap platform described in the literature

• This method allows one-pot interaction screening of antibody libraries and antigen libraries

• Uses microfluidic encapsulation of individual cells with barcoded beads

• Enables identification of interaction partners through sequencing-based analysis

Pull-Down Assays

• Immobilize recombinant CPXM1 on appropriate resin

• Incubate with cell lysates under native conditions

• Wash and elute bound proteins

• Identify partners by mass spectrometry

• Confirm interactions using CPXM1 antibodies in Western blot

Control Experiments

• Include IgG control immunoprecipitations

• Perform reciprocal pull-downs with antibodies against potential partners

• Verify interactions using multiple methodologies

• Consider the role of experimental conditions (detergents, salt concentration)

When interpreting protein-protein interaction data, remember that CPXM1 lacks carboxypeptidase activity , so interactions likely serve structural or regulatory functions rather than substrate-enzyme relationships.

What are the current research applications of CPX1/CPXM1 antibodies in disease studies?

CPXM1 has been implicated in several pathological conditions, making CPX1/CPXM1 antibodies valuable tools for disease-related research:

Neurological Disorders

• CPXM1 is associated with Mirror Movements 1 , suggesting roles in neurological development

• Applications include:

  • Immunohistochemical analysis of CPXM1 distribution in neural tissues

  • Investigation of CPXM1 expression during neurodevelopment

  • Correlation studies between CPXM1 levels and neurological phenotypes

Kidney Disorders

• The association with Nephrotic Syndrome Type 1 indicates potential roles in kidney function

• Research applications include:

  • CPXM1 localization in kidney structures

  • Expression analysis in normal versus diseased kidney tissues

  • Investigation of CPXM1 interactions with kidney-specific proteins

Methodological Approaches in Disease Research

• Tissue microarray analysis: Examine CPXM1 expression across multiple patient samples

• Patient-derived samples: Compare CPXM1 levels between affected and unaffected individuals

• Animal models: Investigate CPXM1 expression and localization in disease models

• Cell-based assays: Study the impact of disease-associated mutations on CPXM1 function

Technical Considerations for Disease Studies

• Include appropriate disease and normal tissue controls

• Consider using multiple detection methods to confirm findings

• Correlate protein expression with genetic information when available

• Document clinical parameters alongside molecular findings

When conducting disease-related research, it's important to validate findings across multiple samples and experimental approaches, as CPXM1's exact role in pathogenesis remains to be fully elucidated.

How should researchers optimize sample preparation for CPX1/CPXM1 detection?

Sample preparation significantly impacts the success of experiments with CPX1/CPXM1 antibodies. Here are methodological considerations for various experimental contexts:

Cell Lysate Preparation

• For Western blot/immunoprecipitation:

  • RIPA buffer for general applications (150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0)

  • For preserving protein-protein interactions, use milder lysis buffers (150 mM NaCl, 1% Triton X-100, 50 mM Tris, pH 7.4)

  • Always include protease inhibitor cocktail

  • Sonicate briefly to shear DNA and reduce viscosity

  • Centrifuge at 14,000 × g for 15 minutes at 4°C to remove debris

Tissue Sample Processing

• Fresh tissue extraction:

  • Mince tissue on ice

  • Homogenize in appropriate buffer with a tissue homogenizer

  • Process immediately to minimize protein degradation

• For immunohistochemistry:

  • Fix tissues in 4% paraformaldehyde or 10% neutral buffered formalin

  • Consider antigen retrieval methods (heat-induced or enzymatic)

  • Test multiple fixation and retrieval methods as they can affect epitope accessibility

Subcellular Fractionation

• Given that CPXM1 may be involved in cell-cell interactions , membrane fraction preparation may be valuable

• Use sequential extraction methods to separate:

  • Cytosolic fraction (isotonic buffer without detergents)

  • Membrane fraction (buffer with mild detergents)

  • Nuclear fraction (high salt extraction)

• Verify fraction purity with compartment-specific markers

Recombinant Protein Handling

• For recombinant Human CPXM1 (Ala21-Asp734) :

  • Reconstitute according to manufacturer's instructions

  • Aliquot to avoid repeated freeze-thaw cycles

  • Use as positive control in experiments

Quality Control Measures

• Quantify protein concentration using BCA or Bradford assay

• Assess protein integrity by Coomassie staining before immunoblotting

• Include positive and negative control samples in each experiment

• Process all experimental samples identically and simultaneously

Optimized sample preparation protocols should be standardized and documented to ensure reproducibility across experiments and between researchers.

What considerations are important when using CPX1/CPXM1 antibodies across different species?

Species cross-reactivity is an important consideration when working with CPX1/CPXM1 antibodies. Here's a methodological approach to cross-species applications:

Understanding Cross-Reactivity Profiles

• Human CPXM1 Biotinylated Antibody shows approximately 30% cross-reactivity with recombinant mouse CPXM1 in Western blots

• Mouse CPXM1 Antibody is specifically designed for mouse samples

• Cross-reactivity with other species should be empirically determined

Sequence Homology Analysis

• Human CPXM1 (Ala21-Asp734, Accession # Q96SM3)

• Mouse CPXM1 (Ala21-Lys722, Accession # Q9Z100)

• The different C-terminal lengths suggest potential structural differences

• Epitope mapping can help predict cross-reactivity

Experimental Validation Across Species

• Western blot validation:

  • Test antibodies against recombinant CPXM1 from multiple species

  • Compare band patterns and intensities

  • Document species-specific molecular weight differences

• Immunohistochemistry/Immunocytochemistry:

  • Validate staining patterns in tissues from different species

  • Compare with known expression patterns from literature

  • Include appropriate positive and negative controls

Optimization Strategies for Cross-Species Applications

• Adjust antibody concentrations for different species

• Modify incubation times and temperatures

• Consider different blocking reagents for reducing background

• Test alternative detection systems

Technical Limitations and Alternatives

• If cross-reactivity is insufficient, consider:

  • Species-specific antibodies when available

  • Peptide-directed custom antibodies against conserved regions

  • Alternative detection methods (e.g., mass spectrometry)

When publishing results from cross-species applications, clearly document the validation experiments performed and any limitations observed in cross-reactivity.

How can researchers utilize CPX1/CPXM1 antibodies in high-throughput screening approaches?

High-throughput screening (HTS) with CPXM1 antibodies can accelerate research by enabling rapid analysis of multiple samples. Here are methodological strategies:

Microarray-Based Approaches

• Reverse-phase protein arrays (RPPA):

  • Spot samples containing CPXM1 on arrays

  • Probe with CPXM1 antibodies for detection

  • Analyze expression across multiple samples simultaneously

• Antibody arrays:

  • Immobilize anti-CPXM1 antibodies on array surfaces

  • Apply samples to detect and quantify CPXM1

  • Useful for screening patient cohorts

Automated Western Blot Systems

• Use capillary-based or microfluidic Western platforms

• Apply CPXM1 antibodies at recommended concentrations (0.1 μg/mL for Human CPXM1 Biotinylated Antibody)

• Increase throughput compared to traditional Western blotting

• Maintain consistency across large sample sets

High-Content Imaging

• Use fluorescently-labeled CPXM1 antibodies for immunocytochemistry

• Employ automated microscopy to analyze multiple samples

• Quantify parameters including:

  • Expression levels

  • Subcellular localization

  • Co-localization with interaction partners

Droplet-Based Single-Cell Analysis

• Adapt the PolyMap/Drop-seq approach described in literature

• This methodology enables:

  • Single-cell encapsulation in microdroplets

  • Barcoded bead-based mRNA capture

  • Generation of barcoded cDNA linking CPXM1 with other genes

  • Deep sequencing analysis of expression patterns

ELISA-Based Screening

• Develop 384-well ELISA protocols using CPXM1 antibodies

• Optimize for miniaturization and automation

• Use for screening:

  • Compound libraries affecting CPXM1 expression

  • Patient samples for biomarker analysis

  • Cell line panels for expression profiling

Quality Control for High-Throughput Applications

• Include technical replicates

• Incorporate positive and negative controls in each plate/array

• Perform pilot studies to determine assay variability

• Establish clear criteria for hit identification

When implementing HTS methods with CPXM1 antibodies, ensure antibody specificity is thoroughly validated before scaling up to prevent false positives and negatives in large-scale screening.

What is the relationship between CPXM1 and its paralog CPXM2?

Understanding the relationship between CPXM1 and its paralog CPXM2 is important for antibody selection and experimental design:

Structural and Functional Comparison

• Both CPXM1 and CPXM2 belong to the carboxypeptidase X family

• Like CPXM1, CPXM2 appears to lack carboxypeptidase activity despite containing a carboxypeptidase domain

• Both proteins contain discoidin domains that may mediate cell-cell or cell-matrix interactions

• Sequence homology creates potential for antibody cross-reactivity

Paralog-Specific Research Considerations

• Antibody specificity:

  • Validate antibodies against both CPXM1 and CPXM2 recombinant proteins

  • Test for cross-reactivity in overexpression systems

  • Consider epitope mapping to identify paralog-specific regions

• Expression pattern differences:

  • Document tissue-specific expression of each paralog

  • Investigate potential functional redundancy

  • Consider compensatory upregulation in knockout models

Methodological Approaches for Paralog Studies

• Co-expression analysis:

  • Use paralog-specific antibodies to examine co-expression in tissues

  • Correlate expression patterns with functional outcomes

  • Investigate potential heterodimer formation

• Functional redundancy testing:

  • Compare phenotypes of single versus double knockdowns

  • Assess rescue experiments with each paralog

  • Examine evolutionary conservation of function

• Interaction partner profiling:

  • Identify shared versus unique binding partners

  • Map interaction domains through mutational analysis

  • Correlate binding profiles with functional differences

When studying CPXM1, always consider the potential involvement of CPXM2, especially when interpreting phenotypes in knockdown/knockout models where compensatory mechanisms may be active .

What methods can researchers use to study post-translational modifications of CPXM1?

Post-translational modifications (PTMs) can significantly impact protein function. Here are methodological approaches to investigate PTMs of CPXM1:

Western Blot-Based PTM Analysis

• Phosphorylation:

  • Use phosphatase treatment of parallel samples

  • Apply phospho-specific antibodies if available

  • Look for mobility shifts in SDS-PAGE

• Glycosylation:

  • Treat samples with glycosidases (PNGase F, Endo H)

  • Observe molecular weight shifts

  • Use lectins to detect specific glycan structures

• Proteolytic processing:

  • Compare apparent molecular weights with predicted sizes

  • Use antibodies recognizing different epitopes

  • Perform N-terminal sequencing of protein fragments

Mass Spectrometry-Based PTM Mapping

• Immunoprecipitate CPXM1 using validated antibodies

• Perform tryptic digestion

• Analyze by LC-MS/MS with PTM-specific search parameters

• Confirm findings with targeted MS approaches

Site-Directed Mutagenesis

• Identify potential PTM sites through in silico prediction

• Generate point mutations at these sites

• Express mutant proteins and assess:

  • Mobility shifts in SDS-PAGE

  • Functional consequences

  • Cellular localization changes

PTM-Specific Enrichment Strategies

• Phosphorylation: Use titanium dioxide or IMAC enrichment

• Glycosylation: Apply lectin affinity chromatography

• Ubiquitination: Employ tandem ubiquitin binding entities (TUBEs)

Correlation with Functional Outcomes

• Examine how PTMs change with:

  • Cell activation states

  • Disease conditions

  • Developmental stages

• Connect PTM patterns to CPXM1's role in cell-cell interactions

Given that CPXM1 lacks carboxypeptidase activity despite having a carboxypeptidase domain , PTMs may play particularly important roles in regulating its non-enzymatic functions.

How can researchers quantitatively analyze CPXM1 expression levels?

Accurate quantification of CPXM1 expression is essential for comparative studies. Here are methodological approaches for quantitative analysis:

Western Blot Densitometry

• Use Human CPXM1 Biotinylated Antibody at 0.1 μg/mL for consistent detection

• Include recombinant CPXM1 standards at known concentrations

• Apply appropriate normalization controls (β-actin, GAPDH)

• Use imaging systems with linear dynamic range

• Analyze band intensity with software like ImageJ or commercial alternatives

Quantitative PCR (qPCR)

• Design primers specific to CPXM1 mRNA

• Validate primer efficiency and specificity

• Use reference genes appropriate for your experimental system

• Apply the comparative Ct (2^-ΔΔCt) method for relative quantification

• Correlate mRNA levels with protein expression using CPXM1 antibodies

ELISA Development

• Use capture and detection antibodies against different CPXM1 epitopes

• Generate standard curves with recombinant CPXM1

• Optimize sample dilutions to fall within the linear range

• Validate assay performance (sensitivity, specificity, reproducibility)

• Apply to biological samples for absolute quantification

Flow Cytometry

• Optimize cell permeabilization if detecting intracellular CPXM1

• Use directly conjugated antibodies or appropriate secondary reagents

• Include fluorescence-minus-one (FMO) controls

• Quantify mean fluorescence intensity (MFI)

• Consider single-cell analysis for heterogeneous populations

Image-Based Quantification

• Apply consistent image acquisition parameters

• Use automated analysis software for unbiased quantification

• Include reference standards in each imaging session

• Report intensity measurements with appropriate statistical analysis

Data Analysis and Presentation

• Perform proper statistical testing appropriate for your experimental design

• Present data with clear indication of biological and technical replicates

• Include measures of variability (standard deviation, standard error)

• Consider data normalization methods appropriate for your experimental system

When reporting quantitative CPXM1 expression data, clearly describe all methodological details to ensure reproducibility.

What experimental approaches can elucidate the role of CPXM1 in disease mechanisms?

Given CPXM1's association with Mirror Movements 1 and Nephrotic Syndrome Type 1 , several experimental approaches can help elucidate its role in disease mechanisms:

Genetic Association Studies

• Analyze CPXM1 variants in patient cohorts

• Correlate genotypes with disease phenotypes

• Perform segregation analysis in affected families

• Use whole exome/genome sequencing to identify novel variants

Functional Characterization of Disease-Associated Variants

• Generate expression constructs with disease-associated mutations

• Assess protein expression, stability, and localization

• Evaluate effects on protein-protein interactions

• Examine impact on cell-cell communication processes

Animal Models

• Develop CPXM1 knockout or knockin mice with disease-associated mutations

• Characterize neurological and renal phenotypes

• Use CPXM1 antibodies to assess protein expression patterns

• Evaluate developmental trajectories in affected systems

Patient-Derived Models

• Establish primary cell cultures from patient samples

• Generate induced pluripotent stem cells (iPSCs) from patients

• Differentiate into relevant cell types (neurons, podocytes)

• Use CPXM1 antibodies to assess protein localization and interactions

Molecular Pathway Analysis

• Identify CPXM1 interaction partners in disease-relevant tissues

• Map signaling pathways affected by CPXM1 dysfunction

• Use phospho-specific antibodies to assess downstream signaling

• Perform transcriptome analysis to identify gene expression changes

Therapeutic Intervention Studies

• Test compounds that modify CPXM1 expression or function

• Assess rescue of disease phenotypes in cellular and animal models

• Monitor CPXM1 levels as biomarkers of treatment response

• Develop targeted approaches based on mechanistic insights

When investigating CPXM1 in disease contexts, integration of multiple experimental approaches provides the most comprehensive understanding of its pathophysiological roles.

What controls and validation steps are essential when publishing research using CPX1/CPXM1 antibodies?

Publication of research using CPX1/CPXM1 antibodies requires rigorous controls and validation to ensure reproducibility and reliability. Here is a comprehensive methodology for antibody validation in publications:

Antibody Characterization Documentation

• Provide complete antibody information:

  • Manufacturer and catalog number

  • Clone number (for monoclonals) or host species (for polyclonals)

  • Lot number (as sensitivity may vary between lots)

  • Concentration used in each application

  • RRID (Research Resource Identifier) when available

Specificity Validation

• Genetic controls:

  • CPXM1 knockout/knockdown samples

  • Overexpression systems

  • Include representative images/blots showing antibody performance

• Immunogen competition:

  • Pre-adsorption with immunizing peptide/protein

  • Demonstrate signal reduction/elimination

• Cross-reactivity assessment:

  • Test against related proteins, particularly CPXM2

  • Document the known 30% cross-reactivity between human CPXM1 antibody and mouse CPXM1

Technical Controls

• For Western blots:

  • Molecular weight markers

  • Loading controls (β-actin, GAPDH)

  • Positive and negative control samples

  • Full blot images with all bands visible

• For immunostaining:

  • Secondary-only controls

  • Isotype controls

  • Autofluorescence controls

  • Known expression pattern references

• For high-throughput methods:

  • Technical and biological replicates

  • Randomization strategies

  • Batch effect controls

Methodology Reporting

• Detailed protocols including:

  • Sample preparation methods

  • Buffer compositions

  • Incubation times and temperatures

  • Washing procedures

  • Image acquisition parameters

  • Quantification methods

Reproducibility Demonstration

• Include data from independent experiments

• Present biological replicates and n numbers clearly

• Apply appropriate statistical analyses

• Consider independent validation using complementary methods

Data Availability

• Provide unprocessed data when possible

• Share detailed protocols via protocols.io or similar platforms

• Consider antibody validation datasets as supplementary material

Following these rigorous validation and reporting guidelines will enhance the reproducibility and impact of research using CPX1/CPXM1 antibodies.